Accretion Nutraveda IPO — Listing Performance
Accretion Nutraveda had a strong market debut, ending listing day 48.22% over the issue price, on tepid subscription of 1.62x.
Accretion Nutraveda IPO facts & figures
| Issue category | SME |
|---|---|
| Issue open date | 28-Jan-2026 |
| Listing date | 04-Feb-2026 |
| Issue size | ₹23.53 crore |
| Overall subscription | 1.62x |
| Issue price | ₹129 |
| Listing-day close | ₹191.20 (48.22%) |
| Recent market price | ₹268.80 (108.37% vs issue) |
| 52-week range | ₹150.10 – ₹300 |
| Identifiers | BSE code: 544694 · ISIN: INE1KVQ01019 |
Figures are compiled from public market data and refreshed when our dataset updates. Verify against BSE/NSE records before acting on them.
How the listing went
Accretion Nutraveda opened for subscription on 28-Jan-2026 as a SME issue raising about ₹24 crore. The shares were priced at ₹129 and made their debut on 04-Feb-2026, closing the first session at ₹191.20 — a listing-day change of 48.22%.
As of our last data refresh the stock trades around ₹268.80, 108.37% above the issue price.
Every IPO in our archive gets this same treatment: real issue data, the actual listing-day result, and where the price stands now — so you can judge how debut hype translated into outcomes. Compare more debuts on the IPO listing-performance archive or check live grey-market sentiment on the GMP board.
Accretion Nutraveda IPO FAQs
What was the Accretion Nutraveda IPO listing price?
Accretion Nutraveda closed at ₹191.20 on its listing day (04-Feb-2026), against an issue price of ₹129 — a listing-day change of 48.22%.
How many times was the Accretion Nutraveda IPO subscribed?
The issue was subscribed about 1.62 times overall.
Was the Accretion Nutraveda IPO profitable for allottees?
On listing day, yes: allottees who sold at the closing price made about 48.22% over the issue price. Longer-term outcomes depend on when shares were sold.